Literature DB >> 31487583

Inhibitory effects of astragaloside IV on silica-induced pulmonary fibrosis via inactivating TGF-β1/Smad3 signaling.

Nannan Li1, Feifei Feng2, Ke Wu3, Huanan Zhang4, Wei Zhang5, Wei Wang6.   

Abstract

PURPOSE: To observe the effect of astragaloside ASV (ASV) on silicosis fibroblasts, and further investigate its regulatory mechanism on TGF-β1/Smad3 signaling pathway.
METHODS: Silica-induced rats model was established in this study. RT-qPCR was performed to detect α-SMA, Collagen I, Collagen III, Smad2, Smad3 and Smad7 expression. Immunofluorescence was conducted to detect α-SMA, Collagen I, Collagen III and p-Smad3 protein and the nucleoplasmic distribution of p-Smad3.Western-blotting was performed to detect the protein of Smad2, p-Smad2, Smad3, p-Smad3 and Smad7.
RESULTS: 20 μg/mL ASV could effectively reduce the expression of α-SMA, Collagen I, Collagen III. TGF-β1 stimulated the proliferation of fibroblasts, promoted phosphorylation of Smad2 and Smad3, and down-regulated Smad7 expression. Among them, continuous phosphorylation of Smad3 is a major factor in causing fibrosis. Besides, ASV can inhibit silica-induced lung fibroblast fibrosis through TGF-β1/Smad3 signaling pathway, thereby inhibiting the formation of silicosis.
CONCLUSION: ASV could inhibit the expression of collagen in fibroblasts and the transformation to myofibroblasts, and has an anti-silicosis fibrosis effect, which may be related to the continuous phosphorylation of Smad3 in the TGF-β1/Smad signaling pathway.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Astragaloside ASV; Extracellular matrix; Pulmonary fibrosis; Silicosis; Transforming growth factor-beta 1

Mesh:

Substances:

Year:  2019        PMID: 31487583     DOI: 10.1016/j.biopha.2019.109387

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  Herbal compounds in the treatment of pulmonary silicosis.

Authors:  J Adamcakova; D Mokra
Journal:  Physiol Res       Date:  2021-12-31       Impact factor: 1.881

2.  Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian
Journal:  Aging (Albany NY)       Date:  2020-03-06       Impact factor: 5.682

3.  Matrix metalloproteinase 3 regulates angiotensin II‑induced myocardial fibrosis cell viability, migration and apoptosis.

Authors:  Jin Shu; Yiwen Gu; Li Jin; Haiya Wang
Journal:  Mol Med Rep       Date:  2020-12-20       Impact factor: 2.952

4.  Astragaloside IV alleviates silica‑induced pulmonary fibrosis via inactivation of the TGF‑β1/Smad2/3 signaling pathway.

Authors:  Nannan Li; Ke Wu; Feifei Feng; Lin Wang; Xiang Zhou; Wei Wang
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

5.  Inhibition of Sirt2 Alleviates Fibroblasts Activation and Pulmonary Fibrosis via Smad2/3 Pathway.

Authors:  Hui Gong; Chenyi Zheng; Xing Lyu; Lini Dong; Shengyu Tan; Xiangyu Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

6.  ZC3H4 regulates infiltrating monocytes, attenuating pulmonary fibrosis through IL-10.

Authors:  Yaping Liu; Xinxin Zhang; Jing Wang; Fuhuang Yang; Wei Luo; Caolong Li; Wei Zhang; Jie Chao; Jie Huang; Mengling Chen; Sha Wang
Journal:  Respir Res       Date:  2022-08-12

7.  Metastasis-associated protein 1 promotes epithelial-mesenchymal transition in idiopathic pulmonary fibrosis by up-regulating Snail expression.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian; Wei Zhang; Li Tian
Journal:  J Cell Mol Med       Date:  2020-03-18       Impact factor: 5.310

8.  Pretreatment with valproic acid alleviates pulmonary fibrosis through epithelial-mesenchymal transition inhibition in vitro and in vivo.

Authors:  Lin Chen; Azeem Alam; Aurelie Pac-Soo; Qian Chen; You Shang; Hailin Zhao; Shanglong Yao; Daqing Ma
Journal:  Lab Invest       Date:  2021-06-24       Impact factor: 5.662

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.